Awards, Pricing of Notes, Partnerships, Medical Technology Developments - Analyst Notes on Cigna, CareFusion, BD, LabCorp and DaVita

LONDON, May 23, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Cigna Corporation (NYSE: CI), CareFusion Corporation (NYSE: CFN), Becton, Dickinson and Co. (NYSE: BDX), Laboratory Corp. of America Holdings (NYSE: LH) and DaVita HealthCare Partners Inc. (NYSE: DVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2857-100free.

--
Cigna  Corporation  Analyst  Notes
On May 14, 2014, Cigna Corporation (Cigna) reported that its business unit, Cigna Medical Group (CMG), was awarded the Daniel T. Cloud Outstanding Practice Award by The Arizona Partnership for Immunization (TAPI) at the 18th Annual Big Shots for Arizona Awards Ceremony. According to the Company, the award recognizes medical offices with 90% immunization levels for the children they serve and 90% of children cared for at six Cigna Medical Group (CMG) offices are up-to-date with their immunizations. "We are proud to receive the Daniel T. Cloud Outstanding Practice Award for the eleventh year," said Andrea Houfek, M.D., Senior Medical Director for CMG. "We are dedicated to making sure the children we care for are protected from vaccine preventable diseases. TAPI's work in the community to educate the public about immunizations is so important, and we are excited to be recognized for such a prestigious award." The full analyst notes on Cigna are available to download free of charge at:
http://www.analystsreview.com/2857-CI-23May2014.pdf

--
CareFusion  Corporation  Analyst  Notes
On May 15, 2014, CareFusion Corporation (CareFusion) announced the pricing of its three series of senior unsecured notes for an aggregate principal amount of $1.0 billion. The Company stated that of these unsecured notes, $300.0 million will mature in 2017 and bear an annual rate interest of 1.450%; $400.0 million will mature in 2024 and bear an annual rate interest of 3.875%; and the remaining $300.0 million will mature in 2044 and bear an annual interest rate of 4.875%. According to the Company, it plans to use a part of the net proceeds to repay its $450.0 million in aggregate outstanding principal amount of 5.125% senior notes due 2014, and use the remaining net proceeds for general corporate purposes. The full analyst notes on CareFusion are available to download free of charge at:
http://www.analystsreview.com/2857-CFN-23May2014.pdf

--
Becton,  Dickinson  and  Co.  Analyst  Notes
On May 20, 2014, Becton, Dickinson and Co. (BD) announced partnership with Island Health to install the BD Kiestra™ Total Lab Automation (TLA) system - a fully-automated microbiology system designed to streamline the entire microbiology testing process and shorten the time to process results, enabling faster access to diagnostic information. Under the agreement, BD Kiestra™ will be installed at the Island Health's Royal Jubilee Hospital by Q4 2014, which makes Island Health the first Regional Health Authority in Canada to implement the system. "BD is proud to be working with Island Health to increase diagnostic efficiencies while delivering better patient outcomes and care," said Lawrence Mahan, Business Director, BD Diagnostics - Diagnostic Systems, BD in Canada. "By implementing the BD Kiestra TLA system, integrated with other rapid diagnostic technologies, Island Health is at the forefront of enabling the fastest possible identification and appropriate treatment of infectious disease." The full analyst notes on BD are available to download free of charge at:
http://www.analystsreview.com/2857-BDX-23May2014.pdf

--
Laboratory  Corp.  of  America  Holdings  Analyst  Notes
On May 19, 2014, Laboratory Corp. of America Holdings (LabCorp) announced the availability of the xTAG® CYP2D6 Kit v3 from Luminex Corporation (Luminex). According to the Company, the xTAG® CYP2D6 Kit v3 is a FDA cleared qualitative genotyping assay that helps clinicians determine strategies for therapeutics metabolized by the CYP2D6 gene product - one of the genes in the cytochrome P450 family of enzymes responsible for metabolizing many drugs. Dr. Mark Brecher, Chief Medical Officer, LabCorp, said, "An individual's CYP2D6 genotype is an important factor to be considered prior to initiating therapy, and Luminex's xTAG CYP2D6 genotype assay will provide clinicians with diagnostic information to help tailor patient specific treatments. Other factors, such as race, ethnicity, diet and potential drug interactions can be determined through observation or reporting, but CYP2D6 genotype can only be assessed through tests like this." The full analyst notes on LabCorp are available to download free of charge at:
http://www.analystsreview.com/2857-LH-23May2014.pdf

--
DaVita  HealthCare  Partners  Inc.  Analyst  Notes
On May 14, 2014, DaVita HealthCare Partners Inc. (DaVita) reported that its division-DaVita Kidney Care was recognized as the national winner in the "Healthcare Personnel Campaign" category by the National Adult and Influenza Summit (NAIIS) at the 2014 Immunization Excellence Awards. The Company stated that these awards recognize individuals and Companies that have made outstanding development towards improving vaccination rates. According to the Company, in 2013 DaVita was the first dialysis provider to implement a comprehensive teammate vaccination order where all of its teammates who frequently visit dialysis centers were required to wear surgical masks or be vaccinated against influenza. Allen R. Nissenson, MD, DaVita's Chief Medical Officer, said, "DaVita's teammate vaccination initiative was an important step in reducing preventable disease outbreaks, reducing unnecessary hospitalizations and increasing our patients'-and our teammates'-quality of life." The full analyst notes on DaVita are available to download free of charge at:
http://www.analystsreview.com/2857-DVA-23May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review